Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.46 |
| ▸ | NEK3 | P51956 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.46 |
| ▸ | NEK5 | Q6P3R8 | 1/20 | 0.46 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.46 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13498298 | 0.91 | HRH3 (0.49) | HRH3SLC5A7 | |
| SCHEMBL1633623 | 0.88 | TBK1 (0.51) | AURKASTK17ANEK3LIMK1NEK5 | |
| SCHEMBL13498345 | 0.85 | SLC5A7 (0.47) | HRH3AURKASTK17ANEK3LIMK1 | |
| SCHEMBL1632568 | 0.85 | HRH3 (0.43) | HRH3 | |
| SCHEMBL1633595 | 0.85 | HRH3 (0.43) | HRH3 | |
| SCHEMBL1634925 | 0.85 | SLC5A7 (0.46) | HRH3AURKASTK17ANEK3LIMK1 | |
| SCHEMBL1632199 | 0.85 | MAP4K1 (0.44) | HRH3 | |
| SCHEMBL1633471 | 0.84 | CDK2 (0.47) | HRH3CCNE1CDK2 | |
| SCHEMBL1634177 | 0.83 | CDK2 (0.47) | HRH3CCNE1CDK2 | |
| SCHEMBL12725011 | 0.83 | TBK1 (0.56) | STK17ANEK3LIMK1NEK5MYLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |